NASDAQ: NRIX Nurix Therapeutics, Inc. 8-K

Nurix holds routine 2026 Annual Meeting, elects three directors with 81% quorum

Filed May 15, 2026 · Period ending May 15, 2026 · ~1 min read

Key Changes

  • low

    Three Class III directors elected to serve until 2029: Arthur T. Sands, Roger Dansey, and Paul M. Silva, all receiving majority stockholder support with approximately 81% of voting shares represented at the meeting.

  • low

    Stockholders ratified PricewaterhouseCoopers LLP as independent auditor for fiscal 2026 with 83.6 million votes in favor, representing strong approval to continue the existing auditor relationship.

  • low

    Executive compensation received stockholder approval in advisory vote, confirming support for the company's compensation practices as detailed in the March 27, 2026 proxy statement.

See the full narrative summary and section-by-section diff — create a free account to read more. Takes 30 seconds.

Partner

Trade NRIX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 9, 2026 4:15 PM